Martin N Scanlon

  • Citations Per Year
Learn More
Blockade of in vitro contractile responses to angiotensins II and III by the reversible competitive angiotensin antagonist [Sar1, Tyr(Me)4]ANG II (sarmesin) was investigated in 3 rat smooth muscle tissues. The pA2 values for sarmesin were: rat uterus, 7.46 +/- 0.04 versus ANG II and 7.46 +/- 0.07 versus ANG III; rat aorta, 7.98 +/- 0.07 versus ANG II and(More)
Treatment of rats for 4 days with alpha-methyldopa, 200 mg/kg/day i.p., increases steady state levels of proopiomelanocortin (POMC) mRNA in the mediobasal hypothalamus, as measured by DNA excess solution hybridization. The increase is prevented by parallel treatment with yohimbine, 2 mg/kg/day i.p., but not by naltrexone, 2 mg/kg/day i.p. Treatment with the(More)
OBJECTIVE To explore the attitudes of family physicians (FPs) toward the use of opioids in the management of chronic noncancer pain (CNCP) in the Calgary Health Region (CHR), Calgary, Alberta. METHODS From January to February 2003, random samples of 147 FPs (32 were used to pretest the instrument and were therefore excluded from the findings) and 142(More)
It is thought that certain actions of ethanol involve an interaction with endogenous opioids, including proopiomelanocortin-derived peptides such as beta-endorphin. To examine this possibility, we used a sensitive and specific assay for proopiomelanocortin mRNA to obtain an estimate of the activity of the endorphinergic system in the mediobasal hypothalamus(More)
The negative feedback control of hypothalamic cortocotrophin releasing factor (CRF) and anterior pituitary proopiomelanocortin (POMC) by corticosteroids is well understood. However, less is known about the mechanisms that regulate POMC gene expression in the arcuate nuclei in the medial basal hypothalamus (MBH). Using a sensitive and specific S1(More)
Receptor blockade with the slowly dissociating angiotensin (ANG) antagonist, [Sar1,Ile8]ANG II, was used to determine dissociation constants (Kd) for angiotensins II and III at receptors in rat isolated uterus, portal vein and aorta. The Kd values obtained were 1) ANG II: uterus, 2.2 +/- 1.2 X 10(-8)M; portal vein, 8.5 +/- 2.5 X 10(-9)M; aorta, 7.8 +/- 1.7(More)
[Sar1, Tyr(Me)4]angiotensin II, synthesized by the solid phase method and purified by ion-exchange chromatography and reversed-phase HPLC, was found to inhibit the contractile response to angiotensin II in the rat isolated uterus and inhibit the pressor response to angiotensin II in the vagotomized ganglion-blocked rat. In the rat isolated uterus Schild(More)
[Cys(S-acetamidomethyl)1,8]angiotensin II has been synthesized by the solid-phase method and purified by carboxymethylcellulose chromatography and reversed-phase HPLC. Treatment of this peptide with iodine gave the cyclic octapeptide [Cys1,8]angiotensin II, which was isolated by Sephadex G-25 chromatography and reversed-phase HPLC. Comparison of the(More)
Analogues of angiotensin II and III (ANG II and ANG III) in which the tyrosine and/or phenylalanine residues were substituted have been synthesized by the solid-phase method and purified by (carboxymethyl)cellulose chromatography and reversed-phase HPLC. The antagonist and agonist potencies of these peptides were determined in the rat isolated uterus assay.(More)
1. Angiotensin-induced contraction of smooth muscle is accompanied by both homotropic (receptor-receptor) and heterotropic (receptor-G protein) cooperativity. 2. Binding constants for angiotensins II and III at uterine smooth muscle receptors have been compared in bioassays and binding assays, using the competitive antagonist Sarmesin to verify the binding(More)